Prevention of cancer by inhibiting aging

被引：83
作者：
Blagosklonny, Mikhail V. [1 ,2 ]
机构：
[1] Ordway Res Inst, Ctr Canc, Albany, NY 12208 USA
[2] Oncotarget, Albany, NY USA
来源：
CANCER BIOLOGY & THERAPY | 2008年 / 7卷 / 10期
关键词：
cancer; aging; rapamycin; metformin; mTOR; calorie restriction; senescence;
D O I：
10.4161/cbt.7.10.6663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aging is associated with cancer, in particular with breast, prostate, colon, lung, stomach, bladder and skin cancer. This article discusses how aging predisposes one to cancer. In principle, inhibition of aging should delay cancer. But is it possible to slow aging? As recently proposed, the nutrient-sensing TOR ( target of rapamycin) pathway is involved in cellular and organismal aging. In rodents, certain conditions that interfere with the TOR pathway slow aging and prevent cancer. Retrospective analysis of clinical data reveals that inhibitors of TOR prevent cancer in humans. This article envisions a potential clinical use of TOR inhibitors in order to slow aging and delay cancer.
引用
收藏
页码：1520 / 1524
页数：5
相关论文
共 103 条
  • [41] Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV β-chemokines:: An approach to suppress R5 strains of HIV-1
    Heredia, A
    Amoroso, A
    Davis, C
    Le, N
    Reardon, E
    Dominique, JK
    Klingebiel, E
    Gallo, RC
    Redfield, RR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) : 10411 - 10416
  • [42] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Hudes, Gary
    Carducci, Michael
    Tomczak, Piotr
    Dutcher, Janice
    Figlin, Robert
    Kapoor, Anil
    Staroslawska, Elzbieta
    Sosman, Jeffrey
    McDermott, David
    Bodrogi, Istvan
    Kovacevic, Zoran
    Lesovoy, Vladimir
    Schmidt-Wolf, Ingo G. H.
    Barbarash, Olga
    Gokmen, Erhan
    O'Toole, Timothy
    Lustgarten, Stephanie
    Moore, Laurence
    Motzer, Robert J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) : 2271 - 2281
  • [43] Ikeno Y, 2003, J GERONTOL A-BIOL, V58, P291
  • [44] Dysregulation of the TSC-mTOR pathway in human disease
    Inoki, K
    Corradetti, MN
    Guan, KL
    [J]. NATURE GENETICS, 2005, 37 (01) : 19 - 24
  • [45] The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span
    Jia, K
    Chen, D
    Riddle, DL
    [J]. DEVELOPMENT, 2004, 131 (16): : 3897 - 3906
  • [46] Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes
    Johnson, JA
    Majumdar, SR
    Simpson, SH
    Toth, EL
    [J]. DIABETES CARE, 2002, 25 (12) : 2244 - 2248
  • [47] Sirolimus: A ten-year perspective
    Kahan, BD
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (01) : 71 - 75
  • [48] Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia
    Kaidi, Abderrahmane
    Qualtrough, David
    Williams, Ann C.
    Paraskeva, Christos
    [J]. CANCER RESEARCH, 2006, 66 (13) : 6683 - 6691
  • [49] Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway
    Kapahi, P
    Zid, BM
    Harper, T
    Koslover, D
    Sapin, V
    Benzer, S
    [J]. CURRENT BIOLOGY, 2004, 14 (10) : 885 - 890
  • [50] Natural history of renal masses followed expectantly
    Kassouf, W
    Aprikian, AG
    Laplante, M
    Tanguay, S
    [J]. JOURNAL OF UROLOGY, 2004, 171 (01) : 111 - 113
12345678910